Skip to main content
Equibles
JANX logo

JANX · Janux Therapeutics, Inc. · Investor Relations

Track JANX — free

Use JANX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JANX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$17.20 +0.46 (+2.75%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$1.05B
Shares
61.14M
Volume · Oct 20 869.47K Avg daily vol (3M) 845.94K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-14 Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
2026-08-06 Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
2026-05-07 Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
2026-04-27 Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
2026-04-16 Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
2026-04-01 Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
2026-02-26 Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-02-17 Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
2026-01-26 Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
2026-01-22 Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
2025-12-23 Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
2025-12-01 Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Past events

Date Event Type
2026-09-11 Cantor Global Healthcare Conference 2026 Fireside Chat Conference
2025-12-01 JANX007 Clinical Data Update Event
2025-09-04 Cantor Global Healthcare Conference 2025 Fireside Chat Conference
2025-07-24 Janux Therapeutics R&D Day Event
2025-05-28 TD Cowen's Virtual Oncology Innovation Summit Event
2025-04-08 Stifel's 2025 Virtual Targeted Oncology Forum Event
2024-12-02 Clinical Data Update Event

Source: https://investors.januxrx.com/

Key facts CIK 1817713 CUSIP 47103J105 13F (30d) 15 filings 15 filers Visit website Investor relations